Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5210 - Nivolumab, ipilimumab and COX2-inhibition in early stage colon cancer

Date

09 Sep 2017

Session

Poster display session

Presenters

Myriam Chalabi

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

M. Chalabi1, M. Van Leerdam2, A. Aalbers3, J. Van den Berg4, G. Beets3, C. Grootscholten1, P. Snaebjornsson4, M. Kuiper1, P. Den Hartog1, F. Weeber5, K. Dijkstra5, M. Kok6, D. Cullen7, T.N.M. Schumacher8, J.B. Haanen1, E. Voest9

Author affiliations

  • 1 Department Of Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 2 Department Of Gastro-enterology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 3 Department Of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 4 Department Of Pathology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 5 Department Of Molecular Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 6 Department Of Medical Oncology, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), 1006 BE - Amsterdam/NL
  • 7 Bms, Bristol-Myers Squibb, 08540 - Princeton/US
  • 8 Department Of Immunology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
  • 9 Medical Oncology, Netherlands Cancer Institute, 1006 BE - Amsterdam/NL
More

Resources

Abstract 5210

Background

For the 4% of patients with metastatic mismatch repair deficient (dMMR) colorectal cancers, impressive responses are seen with anti-PD1 monotherapy, with response rates up to 40%. Data in patients with non-metastatic colon cancers (CCs) are lacking. Both MSS and MSI early stage CCs show a higher proportion of T-cell infiltration, when compared to metastatic disease. Also, preclinical work has shown improved responses to anti-PD1 therapy by addition of COX (2)-inhibition, suggesting this could be a useful adjuvant that might help induce responses in MSS CRCs.

Trial design

The NICHE trial is a single center, investigator-initiated study, in which patients with newly diagnosed colon cancer who have no signs of distant metastases will be treated with short-term immunotherapy ± COX2-inhibition. Treatment will be given in the window period until surgical resection of the tumor. In this exploratory study, the primary objective will be to determine the safety and feasibility of pre-operative immunotherapy in CC. Secondary objectives include exploring the immune activating capacity of immunotherapy in early stage CCs and the added effects of COX2 inhibition, changes in immune suppressive pathways and the correlation of mutational load to putative markers of response. After additional tumor biopsies are taken via endoscopy, patients with dMMR tumors will all be treated with a single dose of ipilimumab 1mg/kg on day 1 and two cycles of nivolumab 3mg/kg on day 1 and 15. Patients with MSS tumors will be randomized to receive celecoxib 200mg once daily in combination with abovementioned treatment. After 5-6 weeks, patients will undergo surgery, where tumor and normal tissue will again be harvested. When deemed advisable by the pathology report, standard adjuvant treatment with chemotherapy will be offered. A total of 30 patients with MSS tumors and 30 patients with MSI tumors will be enrolled. Recruitment for this study is ongoing and currently two patients have been enrolled. Conclusion: This is, to our knowledge, the first study exploring pre-operative immunotherapy in patients with non-metastatic CC and will hopefully help identify mechanisms that interfere with clinical activity of immunotherapy, and to develop future strategies and combinations for CRC.

Clinical trial identification

2016-002940-17. Release date: January 2017

Legal entity responsible for the study

Netherlands Cancer Institute

Funding

Bristol-Myers-Squibb

Disclosure

D. Cullen: Employment with BMS. J.B. Haanen: Ad board BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.